Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001193125-19-039677
Form Type:
13G Filing
Publication Date:
2019-02-14 10:29:02
Filed By:
Clough Capital Partners
Company:
Cardiome Pharma Corp (NASDAQ:CRME)
Filing Date:
2019-02-14
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
CLOUGH CAPITAL PARTNERS 0 2,111,224 0 2,111,224 2,111,224 5.83%
CLOUGH CAPITAL PARTNERS 0 2,111,224 0 2,111,224 2,111,224 5.83%
CHARLES I. CLOUGH, JR 0 2,111,224 0 2,111,224 2,111,224 5.83%
Filing
CUSIP No. 22026V105   13G   Page 1 of 9

 

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.     )*

 

 

Correvio Pharma Corp.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

2206V105

(CUSIP Number)

February 14, 2019

(Date of Event Which Requires Filing of This Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 22026V105   13G   Page 2 of 9

 

  1.  

NAME OF REPORTING PERSONS / I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 

CLOUGH CAPITAL PARTNERS L.P.

  2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(A)  ☐        (B)  ☐

 

  3.  

SEC USE ONLY

 

    

  4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

DELAWARE

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

   5.    

SOLE VOTING POWER

 

0

   6.    

SHARED VOTING POWER

 

2,111,224 (see Item 4)

   7.    

SOLE DISPOSITIVE POWER

 

0

   8.    

SHARED DISPOSITIVE POWER

 

2,111,224 (see Item 4)

  9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

2,111,224 (see Item 4)

10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*  ☐

 

    

11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

5.83% (see Item 4)

12.  

TYPE OF REPORTING PERSON

 

IA Investment Adviser

 


CUSIP No. 22026V105   13G   Page 3 of 9

 

  1.  

NAME OF REPORTING PERSONS / I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 

CLOUGH CAPITAL PARTNERS LLC

  2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(A)  ☐        (B)  ☐

 

  3.  

SEC USE ONLY

 

    

  4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

DELAWARE

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

   5.    

SOLE VOTING POWER

 

0

   6.    

SHARED VOTING POWER

 

2,111,224 (see Item 4)

   7.    

SOLE DISPOSITIVE POWER

 

0

   8.    

SHARED DISPOSITIVE POWER

 

2,111,224 (see Item 4)

  9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

2,111,224 (see Item 4)

10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*  ☐

 

    

11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

5.83% (see Item 4)

12.  

TYPE OF REPORTING PERSON

 

HC Parent Holding Company/Control Person

 


CUSIP No. 22026V105   13G   Page 4 of 9

 

  1.  

NAME OF REPORTING PERSONS / I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 

CHARLES I. CLOUGH, JR.

  2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(A)  ☐        (B)  ☐

 

  3.  

SEC USE ONLY

 

    

  4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

UNITED STATES

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

   5.    

SOLE VOTING POWER

 

0

   6.    

SHARED VOTING POWER

 

2,111,224 (see Item 4)

   7.    

SOLE DISPOSITIVE POWER

 

0

   8.    

SHARED DISPOSITIVE POWER

 

2,111,224 (see Item 4)

  9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

2,111,224 (see Item 4)

10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*  ☐

 

    

11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

5.83% (see Item 4)

12.  

TYPE OF REPORTING PERSON

 

HC Parent Holding Company/Control Person

 


CUSIP No. 22026V105   13G   Page 5 of 9

 

 

ITEM 1.       
  (a)   Name of Issuer: Correvio Pharma Corp.
  (b)   Address of Issuers Principal Executive Offices:
       Justin Renz, CFO
       6th Floor, 1441 Creekside Drive
       Vancouver BC V6J 4S7 Canada
ITEM 2.       
  (a) and (c)    Name and Domicile/Citizenship of Persons Filing:
       (i) Clough Capital Partners L.P., a Delaware limited partnership.
       (ii) Clough Capital Partners LLC, a Delaware limited liability company.
       (iii) Charles I. Clough, Jr., a United States citizen.
  (b)      Each of the Reporting Persons has a business address of:
                   One Post Office Square, 40th Floor, Boston, MA 02109.
  (d)      Title of Class of Securities: Common Stock, par value $0.01 per share.
  (e)      CUSIP Number: 22026V105
ITEM 3.     IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:
  (a)      Broker or Dealer registered under Section 15 of the Act
  (b)      Bank as defined in section 3(a)(6) of the Act
  (c)      Insurance Company as defined in section 3(a)(19) of the Act
  (d)      Investment Company registered under section 8 of the Investment Company Act of 1940
  (e)      Investment Adviser registered under section 203 of the Investment Advisers Act or under the laws of any State
  (f)      Employee Benefit Plan, Pension fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Section 240.13d-1(b)(1)(ii)(F)
  (g)      A Parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G) (Note: See Item 7)
  (h)      A Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act
  (i)      A Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940
  (j)      Group, in accordance with Section 240.13d-1(b)(1)(ii)(J)

CUSIP No. 22026V105   13G   Page 6 of 9

 

ITEM 4.

OWNERSHIP

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
 

(a)    

  

Amount Beneficially Owned: 2,111,224*

 

(b)

  

Percent of Class: 5.83%*

 

(c)

  

Number of shares as to which such person has:

    

(i)

  

sole power to vote or to direct the vote: 0

    

(ii)

  

shared power to vote or to direct the vote: 2,111,224*

    

(iii)

  

sole power to dispose or to direct the disposition of: 0

    

(iv)

  

shared power to dispose or to direct the disposition of: 2,111,224*

 

*

The shares reported above include shares beneficially owned by investment companies, pooled investment vehicles and other accounts for which Clough Capital Partners L.P. serves as investment adviser. Such shares may be deemed beneficially owned by (a) Clough Capital Partners L.P., (b) Clough Capital Partners LLC, the general partner of Clough Capital Partners L.P., and (c) Mr. Clough, the managing member of Clough Capital Partners LLC. Each such reporting person disclaims beneficial ownership of such shares except to the extent of its respective pecuniary interest therein.

The share holding and percent of class data set forth above is reported as of the date of the filing of this statement on Schedule 13G.

 

ITEM 5.

OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐.

 

ITEM 6

OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

Not Applicable.

 

ITEM 7.

IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

See Item 4


CUSIP No. 22026V105   13G   Page 7 of 9

 

ITEM 8.

IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

Not Applicable.

 

ITEM 9.

NOTICE OF DISSOLUTION OF GROUP

Not Applicable.

 

ITEM 10.

CERTIFICATION

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of such securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


CUSIP No. 22026V105   13G   Page 8 of 9

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I hereby certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2019

 

CLOUGH CAPITAL PARTNERS L.P.
By  

Clough Capital Partners LLC,

its general partner

  By:  

    /s/ Charles I. Clough, Jr.

        Charles I. Clough, Jr.,
        managing member

 

CLOUGH CAPITAL PARTNERS LLC

  By:  

    /s/ Charles I. Clough, Jr.

        Charles I. Clough, Jr.,
        managing member
  By:  

    /s/ Charles I. Clough, Jr.

        Charles I. Clough, Jr., individually

Exhibit 1

JOINT FILING AGREEMENT

This Joint Filing Agreement, dated as of February 14, 2019, is by and among Clough Capital Partners L.P., a Delaware limited partnership, Clough Capital Partners LLC, a Delaware limited liability company, and Charles I. Clough, Jr. (the foregoing are collectively referred to herein as the Clough Capital Filers).

Each of the Clough Capital Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G (and amendments thereto) with respect to shares of Common Stock, par value $0.01 per share, of Correvio Pharma Corp., a Canadian corporation, beneficially owned by them from time to time.

Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Clough Capital Filers hereby agree to file a single statement on Schedule 13G (and any amendments thereto) on behalf of each of the Clough Capital Filers, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

This Joint Filing Agreement may be terminated by any of the Clough Capital Filers upon written notice to the other Clough Capital Filers.

Executed and delivered as of the date first above written.

 

CLOUGH CAPITAL PARTNERS L.P.
By  

Clough Capital Partners LLC,

its general partner

  By:  

    /s/ Charles I. Clough, Jr.

        Charles I. Clough, Jr.,
        managing member
CLOUGH CAPITAL PARTNERS LLC
By:  

            /s/ Charles I. Clough, Jr.

 

            Charles I. Clough, Jr.,

            managing member

By:  

            /s/ Charles I. Clough, Jr.

              Charles I. Clough, Jr., individually